Since the start of this year, Moderna (MRNA) has become the hottest stock in the S&P 500, with gains far exceeding 600%. Investors are once again bullish on the company’s growth prospects, and this time the focus is on a cancer vaccine being developed jointly by Moderna and Merck (MRK). Merck’s anticancer drug Keytruda has already generated tens of billions of dollars in revenue, and this vaccine is highly anticipated, with the potential to bring substantial revenue to Moderna and become the long-term growth catalyst it desperately needs. The previous COVID-19 vaccine provided only a temporary boost to the company, whereas this cancer vaccine may offer a more sustainable growth opportunity.
In clinical trials, this vaccine, named intismeran, demonstrated high efficacy in treating melanoma patients when used in combination with Merck’s core anticancer drug Keytruda. Compared with Keytruda alone, the risk of death and melanoma recurrence was reduced by 42%. This result is undoubtedly a major signal of the vaccine’s success. However, this is a personalized vaccine, meaning it cannot easily be mass-produced. Its customized manufacturing process can take up to six weeks, and production costs are expected to be high, making it difficult to enjoy the economies of scale available to other vaccine and drug manufacturers. Based on the melanoma indication, some analysts predict that peak annual sales of the vaccine could exceed $5 billion, but investors may need to lower their expectations regarding launch timing and profitability.
Over the past 12 months, Moderna’s stock price has surged more than 800% and has now recovered to near the level of early 2022. At that time, the market was declining on expectations of slower business growth. Now, with a major potential growth catalyst approaching, market enthusiasm has reignited. However, some argue that investors are once again getting ahead of reality. Approval of intismeran would be a major victory for the company, but given production costs and delivery cycles, it may not deliver substantial profit growth—which has been a major concern in recent years, and 2022 was the company’s most recent year without a loss. Revenue over the past four quarters was $2 billion, and even adding the $5 billion in incremental revenue from intismeran (which will not arrive immediately), annual sales would only be about $7 billion, while the company’s current market value is already close to $90 billion.